Physician profile
Richard E Crum
NPI 1164456570
$5,138.76
in general payments reported to CMS, 2019-2025
27 companies · $700 in 2025
The $700 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,557 · 2020: $202 · 2021: $280 · 2022: $631 · 2023: $930 · 2024: $839 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,469.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $841.96 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $839.81 | 2019-2025 | |
| Pfizer INC. | $468.25 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $427.90 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $355.75 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $309.52 | 2019-2025 | Andexxa, Farxiga, Brilinta |
| Amgen INC. | $199.15 | 2019-2024 | Repatha |
| Astellas Pharma US INC | $198.00 | 2019 | |
| Portola Pharmaceuticals, LLC | $195.71 | 2019 | |
| Edwards Lifesciences Corporation | $190.49 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $171.68 | 2019-2025 | General - Tachy, Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $130.92 | 2024 | Venaseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.14 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $115.42 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $94.47 | 2022-2025 | Verquvo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $89.91 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $65.81 | 2023-2024 | Inpefa |
| Philips North America LLC | $64.89 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
| Biotronik INC. | $54.55 | 2022 | |
| Celonova Biosciences, INC. | $42.98 | 2019-2020 | |
| United Therapeutics Corporation | $34.15 | 2024 | Tyvaso |
| Esperion Therapeutics, INC. | $30.78 | 2021 | |
| Livanova USA, INC. | $24.99 | 2021 | |
| Bridgebio Pharma, INC. | $22.56 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $21.13 | 2023 | Arcalyst |
| Biosense Webster, INC. | $13.22 | 2019 | |
| Medtronic Vascular, INC. | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Crum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.